Scientists Finally Unlock Cancer Mystery Hidden in Gut Bacteria

Breakthrough Discovery After 15 Years of Research

For over a decade, scientists have known that a common gut bacterium called Bacteroides fragilis could trigger colon cancer by releasing a dangerous toxin. But exactly how this toxin invaded healthy colon cells remained one of medicine's most puzzling mysteries—until now.

Since a landmark 2009 study, researchers have known that a common gut bacterium, Bacteroides fragilis, drives colon tumor formation, potentially leading to colorectal cancer, by secreting a toxin that damages the lining of the colon . The study, published April 22 in Nature, reveals that the B. fragilis toxin BFT must first bind host receptor claudin-4 before it can cause damage .

The breakthrough came through an international collaboration led by Johns Hopkins researchers who used cutting-edge CRISPR technology to systematically disable genes in colon cells. By systematically disabling genes in colon epithelial cells, the researchers identified claudin-4 as the critical link . "It took a while to get the assay working and validate the approach, but once we were able to do the screen, claudin-4 was a clear, resounding top hit," says White .

How the Bacterial Toxin Attacks

B. fragilis can be detected in up to 20% of healthy individuals, and has a potent ability to induce colon inflammation and tumor formation . The bacterium accomplishes this damage through a sophisticated two-step process that researchers had never fully understood.

Rather than directly targeting E-cadherin, BFT physically binds claudin-4, which facilitates its proximity to E-cadherin, allowing the protease activity to subsequently cleave and disrupt the epithelial barrier . This discovery was particularly surprising because she and others in the field had long expected the receptor to be a signaling protein, such as a G-coupled protein receptor, which claudin-4 is not. In a literature review, the team could not identify any other toxin that functions this way, as most proteases go straight to their targets rather than binding a separate receptor first .

To confirm their findings, the Johns Hopkins team collaborated with structural biologists in Barcelona. Using biophysical analysis, White and the Barcelona group demonstrated that BFT and claudin-4 form a tight, one-to-one complex in a test tube, providing the first physical evidence of the binding interaction .

A Promising Path to Prevention

The discovery has already yielded a potential treatment strategy. Researchers created molecular "decoys"—fake versions of the claudin-4 receptor that could intercept the toxin before it reached healthy cells. The team created a decoy version of claudin-4, a soluble protein containing claudin-4 sequences, to prevent the toxin from attaching to colon cells. BFT was bound to the decoys instead of the actual receptor, and the strategy successfully protected mice from toxin-related damage .

"This approach could be iterated upon with small molecules or other biologics that have better pharmacological properties," says White . The ability to interfere with the initial molecular event—BFT binding to claudin-4—opens new avenues for designing targeted interventions to inhibit colon inflammation and cancer progression driven by B. fragilis. Moreover, this receptor decoy strategy exemplifies a novel biologic approach, which can be further refined into small molecule inhibitors or antibody-based therapies with enhanced pharmacokinetic profiles .

Implications for Cancer Prevention

This research arrives at a critical time when colorectal cancer rates are rising dramatically among younger adults. The discovery of claudin-4 as the entry point for this cancer-causing toxin opens entirely new possibilities for early detection and prevention strategies.

While one piece of the puzzle remains unsolved— they have not yet captured the precise experimental structure of the interaction between BFT and claudin-4. Current AI modeling systems such as AlphaFold were unable to fully resolve the interaction —the practical applications are already emerging. The research team is now exploring which molecular approaches might be most effective for blocking the toxin entirely.

For millions of people who unknowingly carry this bacterium in their gut, this discovery represents hope that future treatments could prevent cancer before it starts. By understanding exactly how bacterial toxins hijack our cellular machinery, scientists are one step closer to developing targeted therapies that could transform cancer prevention from reactive treatment to proactive protection.